Market
Outcome of U.S. military sales to Israel by December 31, 2025?
3
Resolution / Starting Odds
Sale of advanced weapons approved • 25%
Sale of advanced weapons denied • 25%
No significant sales changes • 25%
New defense agreements • 25%
Official announcements from the U.S. government or credible defense news sources
Story
Trump Weighs Airstrikes and Diplomatic Efforts to Prevent Iran's Nuclear Weapon Development
Dec 13, 2024, 10:43 AM
President-elect Donald Trump is considering military options to prevent Iran from developing nuclear weapons, including potential preventive airstrikes on its nuclear facilities. This shift in policy would break from the long-standing U.S. approach of containing Tehran through diplomacy and sanctions. Trump's transition team is reportedly examining the fall of the Assad regime in Syria, the weakening of Hezbollah and Hamas, and Iran's recent nuclear advancements as factors influencing their strategy. The discussions include two main options: enhancing the U.S. military presence in the Middle East, selling advanced weapons like bunker-busting bombs to Israel, or using the threat of military action combined with sanctions to push for a diplomatic resolution. Iran has warned that any military action would be met with 'maximum resistance.'
View original story
Similar markets
Sale completed as planned • 25%
Sale canceled • 25%
Sale delayed • 25%
Sale modified • 25%
Partially Delivered • 25%
Delayed • 25%
Fully Delivered • 25%
Cancelled • 25%
Same level of support as before • 25%
Decreased support under Biden • 25%
Increased support under Trump • 25%
No change in support • 25%
Increase • 25%
Other • 25%
Remain the same • 25%
Decrease • 25%
No • 50%
Yes • 50%
Sales are delayed • 25%
Proceed as planned • 25%
Sales are canceled • 25%
Sales are reduced • 25%
Delayed • 25%
Sales proceed without change • 25%
Reduced • 25%
Cancelled • 25%
Rejected • 25%
Postponed • 25%
Approved with modifications • 25%
Approved without changes • 25%
Same level of support • 25%
No support • 25%
Decreased support • 25%
Increased support • 25%
Approved with changes • 25%
Rejected • 25%
No decision by deadline • 25%
Approved without changes • 25%